Literature DB >> 19943145

Cost comparison of curative therapies for localized prostate cancer in Japan: a single-institution experience.

Takefumi Satoh1, Hiromichi Ishiyama, Kazumasa Matsumoto, Ken-ichi Tabata, Masashi Kitano, Masatsugu Iwamura, Masaki Kimura, Satoru Minamida, Hideyuki Yamashita, Daisuke Matsuda, Shouko Kotani, Yuzuru Niibe, Mineko Uemae, Kazushige Hayakawa, Shiro Baba.   

Abstract

PURPOSE: In addition to open surgery, curative therapies for prostate cancer now include endoscopic surgery and radiation therapies. Because of the expansion and subdivision of treatment methods for prostate cancer, the medical fee point schedule in Japan was revised in fiscal year 2006. We examined changes in medical income and expenditure after this revision of the medical fee system.
MATERIALS AND METHODS: We studied income and expenditure, after institution of the new medical fee schedule, for the five types of therapies for prostate cancer performed at our hospital: two surgical therapies (radical retropubic prostatectomy and laparoscopic prostatectomy) and three radiation therapies (three-dimensional conformal radiation therapy, (192)Ir high-dose-rate brachytherapy, and (125)I low-dose-rate brachytherapy).
RESULTS: Low-dose-rate brachytherapy was found to be associated with a profit of yen199 per patient. Laparoscopic prostatectomy, a highly advanced medical treatment that the fee revision changed from a partially insured to an insured procedure, yielded a profit of yen75,672 per patient. However, high-dose-rate brachytherapy was associated with a loss of yen654,016 per patient.
CONCLUSION: Given the loss in hospital income per patient undergoing high-dose-rate brachytherapy, the medical fee point system for this procedure should be reassessed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19943145     DOI: 10.1007/s11604-009-0356-x

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  6 in total

1.  Laparoscopic radical prostatectomy: the Montsouris technique.

Authors:  B Guillonneau; G Vallancien
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

2.  Urinary continence following radical prostatectomy.

Authors:  S Egawa; S Minei; M Iwamura; T Uchida; K Koshiba
Journal:  Jpn J Clin Oncol       Date:  1997-04       Impact factor: 3.019

3.  Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience.

Authors:  Vladimir Mouraviev; Israel Nosnik; Leon Sun; Cary N Robertson; Philip Walther; David Albala; Judd W Moul; Thomas J Polascik
Journal:  Urology       Date:  2007-02       Impact factor: 2.649

4.  Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.

Authors:  Takefumi Satoh; Hiromichi Ishiyama; Kazumasa Matsumoto; Hideyasu Tsumura; Masashi Kitano; Kazushige Hayakawa; Shin Ebara; Yasutomo Nasu; Hiromi Kumon; Susumu Kanazawa; Kenta Miki; Shin Egawa; Manabu Aoki; Kazuhito Toya; Atsushi Yorozu; Hirohiko Nagata; Shiro Saito; Shiro Baba
Journal:  BJU Int       Date:  2008-11-25       Impact factor: 5.588

5.  Four-year experience of interstitial permanent brachytherapy for Japanese men with localized prostate cancer.

Authors:  Hiromichi Ishiyama; Takefumi Satoh; Masashi Kitano; Hideyasu Tsumura; Shouko Kotani; Hiroshi Okusa; Mineko Uemae; Shiro Baba; Kazushige Hayakawa
Journal:  Jpn J Clin Oncol       Date:  2008-06-23       Impact factor: 3.019

6.  Delayed recovery of urinary continence after laparoscopic radical prostatectomy.

Authors:  Shin Egawa; Hidetoshi Kuruma; Kazuho Suyama; Masatsugu Iwamura; Shiro Baba
Journal:  Int J Urol       Date:  2003-04       Impact factor: 3.369

  6 in total
  1 in total

1.  Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: the DEGRO-QUIRO trial.

Authors:  Wilfried Budach; Edwin Bölke; Rainer Fietkau; Andre Buchali; Thomas G Wendt; Wolfgang Popp; Christiane Matuschek; Horst Sack
Journal:  Strahlenther Onkol       Date:  2011-07-22       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.